55770-61-1

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Hydroxyphenyl)-2-methylpropanenitrile is used as a pharmaceutical agent for the treatment of inflammatory diseases due to its anti-inflammatory and anti-arthritic properties. It has the potential to be developed into new medications that can alleviate symptoms and improve the quality of life for patients suffering from such conditions.
Used in Medicinal Chemistry Research:
2-(4-Hydroxyphenyl)-2-methylpropanenitrile serves as a subject of interest in medicinal chemistry research. Its unique chemical structure and properties make it a valuable target for the exploration of new drug development strategies and the enhancement of existing treatments for inflammatory diseases. Further research into its mechanism of action and potential synergistic effects with other compounds could lead to breakthroughs in the field of medicinal chemistry.

Upstream product

• 5351-07-5 2-(4-methoxy-phenyl)-2-methyl-propionitrile 
• 80-05-7 BPA 
• 108-95-2 phenol 
• 210551-82-9 2-(4-tert-butyldimethylsilyloxyphenyl)-2-methylpropanenitrile 
• 4286-23-1 4-isopropenylphenol 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 99-93-4 4-Hydroxyacetophenone 
• 104-47-2 p-methoxybenzylnitrile 

Downstream Products

• 29913-51-7 2-methyl-2-(p-hydroxyphenyl)-propionic acid 
• 2955-46-6 2-(4-methoxyphenyl)-2-methylpropanoic acid 
• 51558-25-9 2-methyl-2-[4-(methyloxy)phenyl]-1-propanamine 
• 874775-94-7 C₁₀H₁₄O₂ 
• 676493-85-9 tert-butyl 2-(4-hydroxyphenyl)-2-methylpropylcarbamate 
• 1638114-46-1 C₁₉H₂₃NO₄S₂ 
• 1638114-45-0 C₁₇H₁₉NO₄S 
• 1638114-44-9 C₁₇H₁₇NO₄S 
• 1638114-42-7 C₁₇H₂₁NO₃S 
• 1638114-25-6 C₃₀H₄₂N₂O₇ 
• 1638114-24-5 C₂₀H₁₈N₂O₃ 
• 1638114-23-4 C₂₀H₂₀O₅ 
• 949589-60-0 2-(4-hydroxyphenyl)-2-methylpropanal 
• 5351-07-5 2-(4-methoxy-phenyl)-2-methyl-propionitrile 

Relevant academic research and scientific papers

Synthesis of Tertiary Benzylic Nitriles via Nickel-Catalyzed Markovnikov Hydrocyanation of α-Substituted Styrenes

The Markovnikov hydrocyanation of α-substituted styrenes enables the synthesis of tertiary benzylic nitriles under nickel catalysis. The Lewis-acid-free transformation features an unprecedented functional groups tolerance, including the-OH and-NH2 groups. A broad range of tertiary benzylic nitriles were obtained in good to excellent yields. In addition, an asymmetric version of this reaction was preliminarily investigated.

A biomimetic catalytic aerobic functionalization of phenols

The importance of aromatic C-O, C-N, and C-S bonds necessitates increasingly efficient strategies for their formation. Herein, we report a biomimetic approach that converts phenolic C-H bonds into C-O, C-N, and C-S bonds at the sole expense of reducing dioxygen (O2) to water (H 2O). Our method hinges on a regio- and chemoselective copper-catalyzed aerobic oxygenation to provide ortho-quinones. ortho-Quinones are versatile intermediates, whose direct catalytic aerobic synthesis from phenols enables a mild and efficient means of synthesizing polyfunctional aromatic rings. The direct approach: Polyfunctional aromatic rings have been generated by direct functionalization of C-H bonds to C-O, C-N, and C-S bonds at the sole expense of reducing O2 to H2O. The method hinges on a regio- and chemoselective, copper-catalyzed aerobic oxygenation of phenols to provide ortho-quinones (see scheme), thus mimicking the ubiquitous biosynthetic pathway of melanogenesis.

OXAZOLOBENZIMIDAZOLE DERIVATIVES

The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorde

OXAZOLOBENZIMIDAZOLE DERIVATIVES

The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

1,3-Diethynylallenes: Stable monomers, length-defined oligomers, asymmetric synthesis, and optical resolution

A series of differently substituted 1,3-diethynylallenes (DEAs) have been synthesized, confirming that the previously introduced construction protocols tolerate a variety of functional groups. The new DEAs bear at least one polar group to facilitate enantiomer separations on chiral stationary phases and to allow further functionalization. They are thermally and environmentally stable compounds since bulky substituents next to the cumulene moiety suppress the tendency to undergo [2+2] cyclodimerization. A series of length-defined oligomers were obtained as mixtures of stereoisomers by oxidative coupling of a monomeric DEA under Glaser-Hay conditions. The electronic absorption data indicate a lack of extended π-electron conjugation across the oligomeric backbone due to the orthogonality of the allenic π-systems. Remarkably, even complex mixtures of stereoisomers only yield one single set of NMR signals, which underlines the low stereodifferentiation in acyclic allenoacetylenic structures. Optical resolution of DEAs represents an amazing challenge, and preliminary results on the analytical level are reported. Asymmetric synthesis by Pd-mediated SN2′-type cross-coupling of an alkyne to an optically pure bispropargylic precursor opens another promising route to optically active allenes with stereoselectivities currently reaching up to 78 % ee. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.

DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST

A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3', E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

3-[5-substituted benzyl)amino]-2-phenylpiperidines as substance P antagonists

This invention provides a compound of the formula: STR1 and its pharmaceutically acceptable salts, wherein R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl or terahydropyranyl, having one or more substituents selected from cyano, 1,3-thiazolanyl, COOR 2, COR 2, OCOR 2, CONR 3 R 4, NR 3 R 4, NR 5 COR 3 and C.ident.CR 6, wherein R 2 is hydrogen or C 1 -C 4 alkyl, R 3 and R 4 are independently hydrogen, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl, R 5 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl and R 6 is hydrogen, halo, cyano, C 1 -C 6 alkyl, COOH, COO(C 1 -C 4 alkyl) or phenyl; X is C 1 -C 6 alkoxy or halo C 1 -C 6 alkoxy; and Ar is phenyl optionally substituted with halo.These compounds are useful in the treatment of allergic disorders, angiogenesis, gastrointestinal disorders, central nervous system disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine, sunburn, and diseases, disorders and adverse conditions caused by Helicobacter pylori, in a mammalian subject.

Cyanoisoalkylation of hydroxy substituted aryl compounds using ketones

A method for cyanoisoalkylating phenols or other hydroxy-substituted aryl compounds, which may have up to two substitutents ortho or para to the hydroxy moiety, comprising reacting a molar excess of phenol or aryl compound with a ketone in the presence of

Preparation of cyanoalkylphenols from bisphenols

A process for preparing cyanoalkyphenols comprising contacting a bisphenol with cyanide ion at elevated temperatures under reaction conditions sufficient to produce the desired cyanoalkylphenol. Compounds, e.g. 4-(1-cyano-1-methylethyl)phenol, produce